ClinicalTrials.gg
CompletedNCT06742957Updated Dec 17, 2025

Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis

A Phase 3 interventional study of Tapinarof Cream 1% and VTAMA® in Plaque Type Psorisis, sponsored by Teva Pharmaceuticals USA. Completed at 26 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
560
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 202 studies in Skin Diseases with a site in United States — 32 open to participants now, 49 under way, 9 of them phase 3. Skin Diseases · United States.

Enrollment
14th of 172
560 · median 99
Started
2024
with 12 others
Phase 3
46 of 202
6 open now
Registered
179th of 202
by date

Among the 202 studies in Skin Diseases with a site in United States, this one is the 14th largest by enrollment of the 172 interventional ones that give a count, is one of 13 that started in 2024, is one of 46 in phase 3, and was the 179th registered.

Skin Diseases

497 studies on the registry are indexed under Skin Diseases; 78 are open to participants now.

Browse Skin Diseases studies →

Open to participants now

32 of the 202 studies in Skin Diseases with a site in United States are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 55 Skin Diseases studies recruiting now, 27 (49%) set no upper age limit and 18 (33%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 202 studies in Skin Diseases with a site in United States, or all of them as a file.
02

Study summary

To compare the safety and efficacy of the test (Tapinarof Cream 1%), placebo (vehicle cream) and reference VTAMA® (Tapinarof Cream 1%) treatments to demonstrate clinical equivalence in patients with plaque psoriasis.

Read the detailed description

To compare the safety of Test, Reference, and Placebo treatments in patients with Plaque Psoriasis. Patients in this randomized, double-blind, three-arm, placebo controlled, parallel-design, multi-site study will be randomly assigned in a 2:2:1 ratio to treatment with the test product, reference product or placebo control, respectively.

03

Conditions studied

  • Plaque Type Psorisis

Browse trials for

Keywords

  • Dermatologic Agents
  • Skin Diseases
  • Plaque Psoriasis
  • Tapinarof
  • Adult
  • Phase 3
  • Topical
  • Double-Blind
  • Safety
  • Efficacy
  • Skin Diseases, Papulosquamous
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed ICF indicating that the patient understands the purpose of, and procedures required for the study and is willing to participate in the study.
  2. Males and non-pregnant, non-lactating females aged ≥18 at the time of signing the .
  3. Patients with clinical diagnosis of chronic plaque psoriasis and stable disease for at least 6 months prior to the study.
  4. Body surface area (BSA) involvement ≥ 3% and ≤ 20% (the patient's face, scalp, groins, palms and soles should be excluded from the percent of total BSA (%BSA) calculations).
  5. A Physician's Global Assessment (PGA) score of 2 (mild), 3 (moderate) or 4 (severe) at screening and baseline.
  6. Female patients of (*WOCBP) must not be pregnant or lactating at the time of screening/baseline visit as documented by a negative urine pregnancy test with a sensitivity to at least 25 mIU/ml hCG:

    *Female patients of childbearing potential (WOCBP) are defined as sexually mature women without prior hysterectomy, or who have had any evidence of menses in the past 12 months. However, women who have been amenorrheic for the past 12 or more months are still considered to be of childbearing potential, if the amenorrhea is possibly due to other causes, including prior chemotherapy, anti- estrogens, or ovarian suppression. women (defined as women who have been amenorrheic for at least 12 consecutive months, in the appropriate age group, without other known or suspected primary cause) or women who have been sterilized surgically or who are otherwise proven sterile (i.e., total hysterectomy, or bilateral oophorectomy with surgery at least 4 weeks prior to randomization) are not considered WOCBP. Patients who have undergone tubal ligation are NOT considered as surgically sterile.

  7. Female patients of childbearing potential must be willing to use an acceptable form of during the study from the day of the first dose administration to 30 days after the last administration of study drug.

    1. For the purposes of this study the following are considered acceptable methods of birth control: oral or injectable contraceptives, contraceptive patches, medroxyprogesterone acetate (ex. Depo-Provera®) with stabilized use for at least 3 months, vaginal contraceptive (ex. etonogestrel/ethinyl estradiol vaginal ring (ex. NuvaRing®), contraceptive implant with etonogestrel or equivalent, double barrier methods, (e.g. condom and spermicide), intrauterine device (IUD), true abstinence (if in line with patient's lifestyle).
    2. Patients on hormonal contraception must be stabilized on the same type for at least three months prior to enrollment in the study and must not change the method during the study. A sterile sexual partner is not considered an adequate form of birth control.
    3. If a patient who was abstinent becomes sexually active during the study, a second acceptable method of birth control should be used and documented.
  8. Willing and able to adhere to the lifestyle restrictions specified in this protocol.
  9. Patients must be in good health and free from any disease, which may interfere with the evaluation of plaque psoriasis or the administration of the investigative product.
  10. Patients must be willing to refrain from using all other topical plaque psoriasis products during the 12-week treatment period, other than the product.

Exclusion criteria

Exclusion Criteria:

  1. Known allergies, , or intolerance to any of the ingredients of study treatment interventions, or components/ thereof (refer to the prescribing information of VTAMA®), or drug or other allergy that, in the opinion of the investigator, contraindicates participation in the study.
  2. Current diagnosis of unstable forms of psoriasis (other than plaque variant) in the treatment area, including guttate, erythrodermic, exfoliative or pustular psoriasis.
  3. Patients with other inflammatory skin disease in the treatment area that may confound the evaluation of the plaque psoriasis (e.g., atopic dermatitis, contact dermatitis, tinea corporis, and or any others in the opinion of the Investigator).
  4. Presence of pigmentation, extensive scarring, or pigmented lesions in the treatment areas, which could interfere with the rating of efficacy parameters.
  5. Patients with current .
  6. Ultraviolet (UV) light therapy or prolonged exposure to natural or artificial sources of UV radiation (eg, phototherapy, tanning booths, or therapeutic sunbathing), laser therapy, tattoos removal, skin wraps or exfoliant techniques or Fraxel within 4 weeks prior to the baseline visit and/or plans to have such exposures during the study which could potentially impact the patient's psoriasis (as determined by the Investigator).
  7. Use of biological treatments for psoriasis within the last 6 months of the baseline evaluation.
  8. Patients that have been treated with systemic , systemic antibiotics, systemic anti-psoriatic treatment (i.e., methotrexate, cyclosporine, hydroxyurea), PUVA therapy, ultraviolet- B Therapy or systemic anti-inflammatory agents within 1 month or within 5 half-lives (whichever is longer) before Baseline.
  9. Use of any of the following therapies within two weeks prior to baseline:

    • topical anti-psoriatic drugs (e.g., salicylic acid, anthralin, coal tar, calcipotriene, tazarotene)
    • topical corticosteroids
    • immunosuppressive drugs (e.g., tacrolimus, pimecrolimus)
    • topical retinoids
  10. Received an intervention within 30 days or 5 half-lives prior to the first dose of study intervention, whichever is longer.
  11. Documented medical history of uncontrolled, intercurrent medical condition(s) (i.e., chronic infectious disease, system disorder, organ disorder, cardiovascular, gastrointestinal, hematological, hepatic, neurological, pancreatic, renal disease, severe psychiatric condition, etc.) for which, in the opinion of the investigator, participation would not be in the best interest of the patient (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.
  12. Employees of the Investigator or research center or their immediate family members.
  13. Females who are pregnant, breast feeding, or who wish to become pregnant during the study period.
  14. Patients who have received chemotherapy or radiation therapy and/or anti-neoplastic agents within 3 months prior to screening/baseline.
  15. Patients who are unable or unwilling to give .
  16. Patients, who in the opinion of the Investigator, would be non-compliant with the requirements of the study protocol.
  17. Patients who consume excessive amounts of alcohol (greater than two drinks per day) or use drugs of abuse (including, but not limited to, cannabinoids, cocaine and barbiturates) within one year prior to screening.
  18. Patients who have been previously enrolled in this study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
560 participants (actual)

Study arms

  • Experimental
    Test: Tapinarof Cream 1%

    Tapinarof Cream 1%, Apply a thin layer once daily to psoriatic affected areas for 84 days.

    Drug: Tapinarof Cream 1%

  • Active comparator
    VTAMA®

    (Tapinarof) Cream 1%, Apply a thin layer once daily to psoriatic affected areas for 84 days.

    Drug: VTAMA®

  • Placebo comparator
    Vehicle Product

    Vehicle of the Test Product, Cream, Apply a thin layer once daily to psoriatic affected areas for 84 days.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Primary change in the Physician Global Assessment (PGA)

    Proportion of patients with treatment success (defined as a Physician Global Assessment (PGA) score of clear (0) or almost clear (1) with a minimum 2-grade improvement from baseline at the end of treatment (Week 12; Study Day 84): Score of (0) Clear: No signs of psoriasis; post-inflammatory hyperpigmentation may be present Score of (1) Almost Clear: No thickening; normal to pink coloration; no to minimal focal scaling Score of (2) Mild: Just detectable to mild thickening; pink to light red coloration; predominantly fine scaling Score of (3) Moderate: Clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable erythema; moderate scaling Score of (4) Severe: Severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions

    Time frame: 12 Weeks

07

Study locations

26 sites
  • Site 12107
    Scottsdale, Arizona 85260, United States
  • Site 12101
    Bryant, Arkansas 72022, United States
  • Site 12110
    Dublin, California 94568, United States
  • Site 12112
    Dublin, California 94568, United States
  • Site 12102
    Fremont, California 94538, United States
  • Site 12119
    Huntington Beach, California 92647, United States
  • Site 12120
    Northridge, California 91325, United States
  • Site 12111
    Pomona, California 91767, United States
  • Site 12122
    Greenwich, Connecticut 06831, United States
  • Site 12115
    Fort Lauderdale, Florida 33308, United States
  • Site 12104
    Miami, Florida 33144, United States
  • Site 12116
    Miami, Florida 33146, United States
  • Site 12113
    Miami, Florida 33175, United States
  • Site 12114
    Miramar, Florida 33027, United States
  • Site 12108
    Chicago, Illinois 60614, United States
  • Site 12121
    Rolling Meadows, Illinois 60008, United States
  • Site 12106
    Clarksville, Indiana 47129, United States
  • Site 12123
    Merrillville, Indiana 46410, United States
  • Site 12105
    Louisville, Kentucky 40241, United States
  • Site 12109
    Las Vegas, Nevada 89121, United States
  • 12127
    Woodbury, New York 11797, United States
  • Site 12126
    Portland, Oregon 97210, United States
  • Site 12125
    Upper Saint Clair, Pennsylvania 15241, United States
  • Site 12103
    College Station, Texas 77845, United States
  • Site 12118
    El Paso, Texas 79925, United States
  • Site 12117
    Houston, Texas 77070, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Oct 2025, 9 months.

Of 58 industry-sponsored phase 3 interventional studies under Skin Diseases, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's 9 months is below that.

Counting every sponsor, half of 60 studies reached it within 19 months; a quarter within 13 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2024
First posted
Dec 19, 2024
StartActual
Dec 17, 2024
Primary completionActual
Oct 7, 2025
CompletionActual
Nov 12, 2025
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06742957
Collaborators
Teva Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Dec 19, 2024
Start date
Dec 17, 2024
Primary completion
Oct 7, 2025
Completion
Nov 12, 2025
Last update
Dec 17, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tapinarof

Start the discussion